Preconceptional Paternal Glycidamide Exposure Affects Embryonic Gene
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024
IARC Monographs on the Identification of Carcinogenic Hazards to Humans Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 CONTENTS Introduction ................................................................................................................................... 1 Acetaldehyde (CAS No. 75-07-0) ................................................................................................. 3 Acrolein (CAS No. 107-02-8) ....................................................................................................... 4 Acrylamide (CAS No. 79-06-1) .................................................................................................... 5 Acrylonitrile (CAS No. 107-13-1) ................................................................................................ 6 Aflatoxins (CAS No. 1402-68-2) .................................................................................................. 8 Air pollutants and underlying mechanisms for breast cancer ....................................................... 9 Airborne gram-negative bacterial endotoxins ............................................................................. 10 Alachlor (chloroacetanilide herbicide) (CAS No. 15972-60-8) .................................................. 10 Aluminium (CAS No. 7429-90-5) .............................................................................................. 11 -
National Center for Toxicological Research
National Center for Toxicological Research Annual Report Research Accomplishments and Plans FY 2015 – FY 2016 Page 0 of 193 Table of Contents Preface – William Slikker, Jr., Ph.D. ................................................................................... 3 NCTR Vision ......................................................................................................................... 7 NCTR Mission ...................................................................................................................... 7 NCTR Strategic Plan ............................................................................................................ 7 NCTR Organizational Structure .......................................................................................... 8 NCTR Location and Facilities .............................................................................................. 9 NCTR Advances Research Through Outreach and Collaboration ................................... 10 NCTR Global Outreach and Training Activities ............................................................... 12 Global Summit on Regulatory Science .................................................................................................12 Training Activities .................................................................................................................................14 NCTR Scientists – Leaders in the Research Community .................................................. 15 Science Advisory Board ................................................................................................... -
Interplay Between Epigenetics and Metabolism in Oncogenesis: Mechanisms and Therapeutic Approaches
OPEN Oncogene (2017) 36, 3359–3374 www.nature.com/onc REVIEW Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches CC Wong1, Y Qian2,3 and J Yu1 Epigenetic and metabolic alterations in cancer cells are highly intertwined. Oncogene-driven metabolic rewiring modifies the epigenetic landscape via modulating the activities of DNA and histone modification enzymes at the metabolite level. Conversely, epigenetic mechanisms regulate the expression of metabolic genes, thereby altering the metabolome. Epigenetic-metabolomic interplay has a critical role in tumourigenesis by coordinately sustaining cell proliferation, metastasis and pluripotency. Understanding the link between epigenetics and metabolism could unravel novel molecular targets, whose intervention may lead to improvements in cancer treatment. In this review, we summarized the recent discoveries linking epigenetics and metabolism and their underlying roles in tumorigenesis; and highlighted the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these abnormalities in cancer. Oncogene (2017) 36, 3359–3374; doi:10.1038/onc.2016.485; published online 16 January 2017 INTRODUCTION metabolic genes have also been identified as driver genes It has been appreciated since the early days of cancer research mutated in some cancers, such as isocitrate dehydrogenase 1 16 17 that the metabolic profiles of tumor cells differ significantly from and 2 (IDH1/2) in gliomas and acute myeloid leukemia (AML), 18 normal cells. Cancer cells have high metabolic demands and they succinate dehydrogenase (SDH) in paragangliomas and fuma- utilize nutrients with an altered metabolic program to support rate hydratase (FH) in hereditary leiomyomatosis and renal cell 19 their high proliferative rates and adapt to the hostile tumor cancer (HLRCC). -
Catalysis by the Jmjc Histone Demethylase KDM4A Integrates Substrate Dynamics, Correlated Motions Cite This: Chem
Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue Catalysis by the JmjC histone demethylase KDM4A integrates substrate dynamics, correlated motions Cite this: Chem. Sci., 2020, 11, 9950 † All publication charges for this article and molecular orbital control have been paid for by the Royal Society a a b of Chemistry Rajeev Ramanan, Shobhit S. Chaturvedi, Nicolai Lehnert, Christopher J. Schofield, c Tatyana G. Karabencheva-Christova *a and Christo Z. Christov *a 3 The N -methyl lysine status of histones is important in the regulation of eukaryotic transcription. The Fe(II) and 2-oxoglutarate (2OG) -dependent JmjC domain enzymes are the largest family of histone N3-methyl lysine demethylases (KDMs). The human KDM4 subfamily of JmjC KDMs is linked with multiple cancers and some of its members are medicinal chemistry targets. We describe the use of combined molecular dynamics (MD) and Quantum Mechanical/Molecular Mechanical (QM/MM) methods to study the mechanism of KDM4A, which catalyzes demethylation of both tri- and di-methylated forms of histone Creative Commons Attribution-NonCommercial 3.0 Unported Licence. H3 at K9 and K36. The results show that the oxygen activation at the active site of KDM4A is optimized towards the generation of the reactive Fe(IV)-oxo intermediate. Factors including the substrate binding mode, correlated motions of the protein and histone substrates, and molecular orbital control synergistically contribute to the reactivity of the Fe(IV)-oxo intermediate. In silico substitutions were performed to investigate the roles of residues (Lys241, Tyr177, and Asn290) in substrate orientation. The Lys241Ala substitution abolishes activity due to altered substrate orientation consistent with reported experimental studies. -
Mutant IDH, (R)-2-Hydroxyglutarate, and Cancer
Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer Julie-Aurore Losman1 and William G. Kaelin Jr.1,2,3 1Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA; 2Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA Mutations in metabolic enzymes, including isocitrate whether altered cellular metabolism is a cause of cancer dehydrogenase 1 (IDH1) and IDH2, in cancer strongly or merely an adaptive response of cancer cells in the face implicate altered metabolism in tumorigenesis. IDH1 of accelerated cell proliferation is still a topic of some and IDH2 catalyze the interconversion of isocitrate and debate. 2-oxoglutarate (2OG). 2OG is a TCA cycle intermediate The recent identification of cancer-associated muta- and an essential cofactor for many enzymes, including tions in three metabolic enzymes suggests that altered JmjC domain-containing histone demethylases, TET cellular metabolism can indeed be a cause of some 5-methylcytosine hydroxylases, and EglN prolyl-4-hydrox- cancers (Pollard et al. 2003; King et al. 2006; Raimundo ylases. Cancer-associated IDH mutations alter the enzymes et al. 2011). Two of these enzymes, fumarate hydratase such that they reduce 2OG to the structurally similar (FH) and succinate dehydrogenase (SDH), are bone fide metabolite (R)-2-hydroxyglutarate [(R)-2HG]. Here we tumor suppressors, and loss-of-function mutations in FH review what is known about the molecular mechanisms and SDH have been identified in various cancers, in- of transformation by mutant IDH and discuss their im- cluding renal cell carcinomas and paragangliomas. -
Chemistry and Safety of Acrylamide in Food ADVANCES in EXPERIMENTAL MEDICINE and BIOLOGY
Chemistry and Safety of Acrylamide in Food ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY Editorial Board: NATHAN BACK, State University of New York at Buffalo IRUN R. COHEN, The Weizmann Institute of Science DAVID KRITCHEVSKY, Wistar Institute ABEL LAJTHA, N. S. Kline Institute for Psychiatric Research RODOLFO PAOLETTI, University of Milan Recent Volumes in this Series Volume 553 BIOMATERIALS: From Molecules to Engineered Tissues Edited by Nesrin Hasirci and Vasif Hasirci Volume 554 PROTECTING INFANTS THROUGH HUMAN MILK: Advancing the Scientific Evidence Edited by Larry K. Pickering, Ardythe L. Morrow, Guillermo M. Ruiz-Palacios, and Richard J. Schanler Volume 555 BREAST FEEEDING: Early Influences on Later Health Edited by Gail Goldberg, Andrew Prentice, Ann Prentice, Suzanne Filteau, and Elsie Widdowson Volume 556 IMMUNOINFORMATICS: Opportunities and Challenges of Bridging Immunology with Computer and Information Sciences Edited by Christian Schoenbach, V. Brusic, and Akihiko Konagaya Volume 557 BRAIN REPAIR Edited by M. Bahr Volume 558 DEFECTS OF SECRETION IN CYSTIC FIBROSIS Edited by Carsten Schultz Volume 559 CELL VOLUME AND SIGNALING Edited by Peter K. Lauf and Norma C. Adragna Volume 560 MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION X: INNATE IMMUNITY Edited by Sudhir Gupta, William Paul, and Ralph Steinman Volume 561 CHEMISTRY AND SAFETY OF ACRYLAMIDE IN FOOD Edited by Mendel Friedman and Don Mottram A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher. Chemistry and Safety of Acrylamide in Food Edited by Mendel Friedman Agricultural Research Service, USDA Albany, California and Don Mottram University of Reading Reading, United Kingdom Spriinge r Library of Congress Cataloging-in-Publication Data Chemistry and safety of acrylamide in food/edited by Mendel Friedman and Don Mottram. -
Towards Next Generation Risk Assessment of Chemicals: Bayesian
Towards next generation risk assessment of chemicals : bayesian meta-analysis of human variability in metabolism and transporters and application for the derivation of pathway-related uncertainty factors Keyvin Darney To cite this version: Keyvin Darney. Towards next generation risk assessment of chemicals : bayesian meta-analysis of human variability in metabolism and transporters and application for the derivation of pathway- related uncertainty factors. Toxicology. Université de Bretagne occidentale - Brest, 2020. English. NNT : 2020BRES0013. tel-03227086 HAL Id: tel-03227086 https://tel.archives-ouvertes.fr/tel-03227086 Submitted on 16 May 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THESE DE DOCTORAT DE L'UNIVERSITE DE BRETAGNE OCCIDENTALE ECOLE DOCTORALE N° 605 Biologie Santé Spécialité : Toxicologie Par Keyvin DARNEY Towards next generation risk assessment of chemicals: Bayesian meta-analysis of Human variability in metabolism and transporters and application for the derivation of pathway-related uncertainty factors Thèse présentée -
Dietary Intake and Biomarkers of Acrylamide Exposure and Risk of Endometrial and Ovarian Cancer
Dietary intake and biomarkers of acrylamide exposure and risk of endometrial and ovarian cancer A molecular epidemiologic study in the European Prospective Investigation into Cancer and Nutrition Mireia Obón Santacana Aquesta tesi doctoral està subjecta a la llicència Reconeixement- NoComercial – SenseObraDerivada 3.0. Espanya de Creative Commons. Esta tesis doctoral está sujeta a la licencia Reconocimiento - NoComercial – SinObraDerivada 3.0. España de Creative Commons. This doctoral thesis is licensed under the Creative Commons Attribution-NonCommercial- NoDerivs 3.0. Spain License. REFERENCE LIST REFERENCE LIST 8. REFERENCE LIST 1. (1986) Acrylamide. IARC Monogr Eval Carcinog Risk Chem Hum 39:41–66. 2. Chen Y-H, Xia E-Q, Xu X-R, et al (2012) Evaluation of Acrylamide in Food from China by a LC/MS/MS Method. Int J Environ Res Public Health 9:4150–4158. doi: 10.3390/ijerph9114150 3. IARC (1994) IARC working group on the evaluation of carcinogenic risks to humans: some industrial chemicals. Lyon, 15-22 February 1994. IARC Monogr EvalCarcinogRisks Hum 60:1–560. 4. Sobel W, Bond GG, Parsons TW, Brenner FE (1986) Acrylamide cohort mortality study. Br J Ind Med 43:785–788. 5. Collins JJ, Swaen GM, Marsh GM, et al (1989) Mortality patterns among workers exposed to acrylamide. J Occup Med 31:614–617. 6. Le Quesne PM (1985) Clinical and morphological findings in acrylamide toxicity. Neurotoxicology 6:17–24. 7. Reynolds T (2002) Acrylamide and cancer: tunnel leak in Sweden prompted studies. J Natl Cancer Inst 94:876–878. 8. Törnqvist M, Bergmark E, Ehrenberg L, Granath F (1998) Risk assessment of acrylamide. -
National Center for Toxicological Research Annual Report 2019
National Center for Toxicological Research 2019 Annual Report Vision, Mission, and Goals Vision The U.S. Food and Drug Administration’s National Center for Toxicological Research is a global resource for collaboration—providing consultation, training, and innovative scientific solutions in support of FDA’s mission to improve public health. Mission NCTR conducts scientific research to generate data for FDA decision making, and develops and supports innovative tools and approaches that FDA uses to protect and promote individual and public health. NCTR Research Goals 2019 NCTR Annual Report Table of Contents (Please click on any of the sections below to quickly visit that section) 4 Preface ─ Message from the Director 5 Preface ─ About the Annual Report 6 NCTR Organization Structure ─ NCTR Leadership 7 NCTR Organization Structure ─ Research Division Directors 8 NCTR at a Glance 9 NCTR at a Glance ─ Numbers for 2019 12 2019 Research Collaborations 13 Collaborations ─ CDER 15 Collaborations ─ CTP 16 Collaborations ─ CFSAN 17 Collaborations ─ CVM 18 Collaborations ─ ORA 19 Collaborations ─ NIEHS/NTP 20 Science Advisory Board 21 Perinatal Health Center of Excellence 22 Global Summit on Regulatory Science (GSRS) 23 2019 NCTR Research Divisions and Important Accomplishments 24 Biochemical Toxicology 26 Bioinformatics & Biostatistics 28 Genetic & Molecular Toxicology 30 Microbiology 32 Neurotoxicology 34 Systems Biology 36 Office of Scientific Coordination www.fda.gov/nctr Message from the Director Preface The National Center for Toxicological Research (NCTR) is the U.S. Food and Drug Administration’s (FDA) premier laboratory research center focused on all FDA-regulated products. NCTR’s primary goal is to support FDA, a critical component of the Department of Health and Human Services (HHS), in its efforts to promote and protect the health of the American public. -
1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A -
Maternal Expression of the Histone Demethylase Kdm4a Is Crucial For
© 2017. Published by The Company of Biologists Ltd | Development (2017) 144, 3264-3277 doi:10.1242/dev.155473 RESEARCH ARTICLE Maternal expression of the histone demethylase Kdm4a is crucial for pre-implantation development Aditya Sankar1,2,3,*,§, Susanne Marije Kooistra1,2,‡,§, Javier Martin Gonzalez4, Claes Ohlsson6, Matti Poutanen5,6 and Kristian Helin1,2,3,¶ ABSTRACT residue, as well as type and degree of modification (Greer and Shi, Regulation of chromatin composition through post-translational 2012; Kooistra and Helin, 2012; Dimitrova et al., 2015). modifications of histones contributes to transcriptional regulation Similar to the other members of the JMJD2/KDM4 family of and is essential for many cellular processes, including differentiation histone demethylases, KDM4A is capable of removing di- and tri- and development. KDM4A (JMJD2A) is a lysine demethylase with methylation from lysines 9 and 36 of histone H3 (Cloos et al., 2006; specificity towards di- and tri-methylated lysine 9 and lysine 36 of Klose et al., 2006; Whetstine et al., 2006; Chen et al., 2006, 2007; histone H3 (H3K9me2/me3 and H3K36me2/me3). Here, we report Ng et al., 2007). KDM4A, like KDM4C, binds to tri-methylated that Kdm4a as a maternal factor plays a key role in embryo survival lysine 4 on histone H3 (H3K4me3) through its double Tudor and is vital for female fertility. Kdm4a−/− female mice ovulate normally domain (Huang et al., 2006; Pedersen et al., 2016, 2014). In this with comparable fertilization but poor implantation rates, and cannot way, the KDM4 proteins provide a failsafe mechanism to prevent support healthy transplanted embryos to term. This is due to a role for spurious accumulation of H3K9me3 at active promotors, thereby Kdm4a in uterine function, where its loss causes reduced expression maintaining transcriptional competence (Pedersen et al., 2016). -
Electronic Supplementary Material (ESI) for Metallomics
Electronic Supplementary Material (ESI) for Metallomics. This journal is © The Royal Society of Chemistry 2018 Uniprot Entry name Gene names Protein names Predicted Pattern Number of Iron role EC number Subcellular Membrane Involvement in disease Gene ontology (biological process) Id iron ions location associated 1 P46952 3HAO_HUMAN HAAO 3-hydroxyanthranilate 3,4- H47-E53-H91 1 Fe cation Catalytic 1.13.11.6 Cytoplasm No NAD biosynthetic process [GO:0009435]; neuron cellular homeostasis dioxygenase (EC 1.13.11.6) (3- [GO:0070050]; quinolinate biosynthetic process [GO:0019805]; response to hydroxyanthranilate oxygenase) cadmium ion [GO:0046686]; response to zinc ion [GO:0010043]; tryptophan (3-HAO) (3-hydroxyanthranilic catabolic process [GO:0006569] acid dioxygenase) (HAD) 2 O00767 ACOD_HUMAN SCD Acyl-CoA desaturase (EC H120-H125-H157-H161; 2 Fe cations Catalytic 1.14.19.1 Endoplasmic Yes long-chain fatty-acyl-CoA biosynthetic process [GO:0035338]; unsaturated fatty 1.14.19.1) (Delta(9)-desaturase) H160-H269-H298-H302 reticulum acid biosynthetic process [GO:0006636] (Delta-9 desaturase) (Fatty acid desaturase) (Stearoyl-CoA desaturase) (hSCD1) 3 Q6ZNF0 ACP7_HUMAN ACP7 PAPL PAPL1 Acid phosphatase type 7 (EC D141-D170-Y173-H335 1 Fe cation Catalytic 3.1.3.2 Extracellular No 3.1.3.2) (Purple acid space phosphatase long form) 4 Q96SZ5 AEDO_HUMAN ADO C10orf22 2-aminoethanethiol dioxygenase H112-H114-H193 1 Fe cation Catalytic 1.13.11.19 Unknown No oxidation-reduction process [GO:0055114]; sulfur amino acid catabolic process (EC 1.13.11.19) (Cysteamine